Genmab | GEN - Cost Of Sales


Genmab reported DKK81M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Almirall EUR 191.5M 2.29M Dec/2025
Amarin USD 26.05M 1.41M Dec/2025
Amgen USD 1.6B 187M Mar/2026
argenx SE USD 121M 28.69M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Bayer EUR 5.23B 731M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Demant DKK 2.89B 188M Dec/2025
Exelixis USD 19.95M 6.53M Mar/2026
Fresenius Medical Care EUR 3.43B 248M Mar/2026
Genmab DKK 81M 23M Dec/2025
GlaxoSmithKline GBP 1.88B 736M Mar/2026
GN Store Nord DKK 1.16B 1.08B Mar/2026
GRIFOLS EUR 1.08B 214.82M Mar/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Insmed USD 49.5M 3.34M Mar/2026
Lakefront Biotherapeutics EUR 4.8M 4.34M Mar/2026
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.07B 219M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
UCB EUR 1.07B 146M Dec/2025